TCGA-CV-6952-01A-11R-1915-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.042237443
- sex
- female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.730
- INTERFERON_GAMMA_RESPONSE+0.600
- TNFA_SIGNALING_VIA_NFKB+0.430
- PROTEIN_SECRETION+0.380
- IL6_JAK_STAT3_SIGNALING+0.350
- CHOLESTEROL_HOMEOSTASIS+0.340
- INFLAMMATORY_RESPONSE+0.340
- MYOGENESIS+0.340
- TGF_BETA_SIGNALING+0.330
- ALLOGRAFT_REJECTION+0.310
Top 10 suppressed
- E2F_TARGETS-0.260
- SPERMATOGENESIS-0.260
- PEROXISOME-0.220
- OXIDATIVE_PHOSPHORYLATION-0.170
- ADIPOGENESIS-0.160
- G2M_CHECKPOINT-0.160
- PANCREAS_BETA_CELLS-0.140
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.130
- DNA_REPAIR-0.090
- BILE_ACID_METABOLISM-0.070
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-CQ-A4C6-01A-11R-A24Z-07 | — | — | 0.875 |
| 2 | SRR25043629 | — | — | 0.858 |
| 3 | BS_5AF6ZNJF | Meningioma | — | 0.843 |
| 4 | BS_E94QRJDW | low-grade glioma | — | 0.835 |
| 5 | TCGA-CN-6998-01A-23R-2016-07 | — | — | 0.829 |
| 6 | BS_X91K8KMG | pilocytic astrocytoma | — | 0.828 |
| 7 | TCGA-K4-A6FZ-01A-11R-A31N-07 | — | — | 0.823 |
| 8 | TCGA-CR-7395-01A-11R-2016-07 | — | — | 0.823 |
| 9 | BS_HX0S30NE | pilocytic astrocytoma | — | 0.823 |
| 10 | TCGA-CQ-7063-01A-11R-2403-07 | — | — | 0.821 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.730 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.600 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.430 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.380 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.350 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.340 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.340 | Idelalisib | — uncovered |
| MYOGENESIS | 0.340 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.330 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.310 | Idelalisib | — uncovered |
| COMPLEMENT | 0.310 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.280 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.260 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.250 | Inavolisib | — uncovered |
| APOPTOSIS | 0.250 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.240 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.240 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.210 | Inavolisib | — uncovered |
| HYPOXIA | 0.210 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.200 | Inavolisib | — uncovered |